AIM ImmunoTech (AIM) News Today $0.16 0.00 (-2.42%) Closing price 04:10 PM EasternExtended Trading$0.16 0.00 (0.00%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings AIM ImmunoTech Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdaysOctober 7, 2026 | finance.yahoo.comAIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdaysOctober 7, 2026 | globenewswire.comAim Immunotech Inc. Highlights Recent Media Coverage of Ampligen?S Broad-Spectrum Antiviral and Biodefense PotentialOctober 6, 2026 | marketscreener.comMAIM ImmunoTech Highlights Recent Media Coverage of Ampligen's Broad-Spectrum Antiviral and Biodefense PotentialOctober 6, 2026 | marketscreener.comMAIM ImmunoTech Highlights Ampligen's Broad-Spectrum Antiviral PotentialOctober 5, 2026 | rttnews.comAIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense PotentialOctober 5, 2026 | markets.businessinsider.comAIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense PotentialOctober 5, 2026 | globenewswire.comAIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline DataOctober 1, 2026 | globenewswire.comAIM ImmunoTech Inc. Releases New CEO Corner Segment Discussing Ampligen?s Potential To Complement Emerging Pancreatic Cancer TherapiesOctober 1, 2026 | marketscreener.comMIonic Rare Earths targets AIM listing as Belfast magnet recycling strategy gathers paceSeptember 30, 2026 | proactiveinvestors.comAIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner VideoSeptember 30, 2026 | markets.businessinsider.comAIM ImmunoTech Discusses Ampligen®'s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner VideoSeptember 30, 2026 | globenewswire.comOndine Biomedical pauses trading to raise fresh investment after positive phase III resultSeptember 30, 2026 | proactiveinvestors.comAIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ DaraxonrasibSeptember 22, 2026 | markets.businessinsider.comShore Capital cheers Coiled Therapeutics dosing progressSeptember 21, 2026 | proactiveinvestors.comCoiled Therapeutics fills two cohorts as reworked cancer drug advancesSeptember 21, 2026 | proactiveinvestors.comAIM ImmunoTech Reduces Debt via Equity Exchange AgreementsSeptember 12, 2026 | theglobeandmail.comAIM ImmunoTech Inc.: AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen in Pancreatic Cancer in New CEO Corner VideoSeptember 9, 2026 | finanznachrichten.deAIM ImmunoTech Advances Ampligen In Phase 2 Pancreatic Cancer StudySeptember 9, 2026 | rttnews.comAIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner VideoSeptember 9, 2026 | globenewswire.comAIM ImmunoTech Secures Europe, U.K. Patent Protection For Ampligen In Long COVID; Shares JumpSeptember 3, 2026 | rttnews.comAIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041September 2, 2026 | globenewswire.comAIM ImmunoTech Secures Broad U.S. Patent For Ampligen In Combination With Keytruda; Stock UpAugust 31, 2026 | rttnews.comAIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen ...August 31, 2026 | markets.businessinsider.comAIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039August 31, 2026 | globenewswire.comÉléments financiers clés - AIMAugust 29, 2026 | fr.investing.comAIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand ConferenceAugust 27, 2026 | finance.yahoo.comAIM ImmunoTech Participates in the Virtual Investor 'Why Now' On-Demand ConferenceAugust 27, 2026 | tmcnet.comAIM ImmunoTech Participates in the Virtual Investor ‘Why Now' On-Demand ConferenceAugust 27, 2026 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: AIM ImmunoTech (AIM), Niagen Bioscience (NAGE)August 26, 2026 | theglobeandmail.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: AIM ImmunoTech (AIM) and Schrodinger (SDGR)August 13, 2026 | theglobeandmail.comAIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ ArticleAugust 12, 2026 | markets.businessinsider.comAIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense' ArticleAugust 12, 2026 | globenewswire.comAIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in ...August 10, 2026 | markets.businessinsider.comAIM ImmunoTech Ends At-The-Market Equity ProgramAugust 5, 2026 | tipranks.comAIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection PointAugust 3, 2026 | markets.businessinsider.comAIM ImmunoTech Ahead of Schedule on ‘Last Dose' DURIPANC Critical Clinical Inflection PointAugust 3, 2026 | globenewswire.comAIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer ProgramJuly 7, 2026 | globenewswire.comAIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical MilestonesJune 24, 2026 | globenewswire.comAIM Sports Group's National SoCal Cup ‘The Showcase' Event Serves Up a Weekend of New ExperiencesJune 23, 2026 | businesswire.comAIM ImmunoTech to Present in the Webull Corporate Connect Webinar SeriesJune 22, 2026 | globenewswire.comAIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic CancerJune 18, 2026 | globenewswire.comAIM Talks China 2026 Convenes in Guangzhou, Advancing Strategic Partnerships and Cross Border Investment Across the Greater Bay AreaJune 17, 2026 | globenewswire.comAIM ImmunoTech Inc.: AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity DeficiencyJune 15, 2026 | finanznachrichten.deAIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity DeficiencyJune 15, 2026 | globenewswire.comAIM ImmunoTech Raises Capital via Registered Direct OfferingJune 11, 2026 | tipranks.comInfosys Collaborates with CMMI Institute to Shape Enterprise AI Maturity Framework; Achieves Milestone RecognitionJune 11, 2026 | prnewswire.comAIM ImmunoTech Updates Bylaws on Shareholder Voting StandardsJune 10, 2026 | tipranks.comAIM ImmunoTech Inc. Announces $2.65 Million Registered Direct Offering and Private PlacementJune 9, 2026 | quiverquant.comQAIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American RulesJune 9, 2026 | globenewswire.com AIM ImmunoTech Media Mentions By Week AIM ImmunoTech Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AIM News Sentiment▼1.000.66▲Average Healthcare News Sentiment AIM ImmunoTech News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AIM Articles This Week▼23▲AIM Articles Average Week AIM ImmunoTech Trends on MarketBeatThis week vs. last weekNew Followers2Searches2-33%Page Views1,548+1% Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies NEUP News AKTX News BYSI News MRKR News NXTC News BKHA News ATYR News JSPR News DYAI News APLT News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for AIM ImmunoTech dated 10/7/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredElon Musk's Intel Deal Already Jumped 177 Percent This YearElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | Sponsored$29.97 or $0 todayThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
